-
Saving the lives of severe COVID-19 patients WHO recommends IL-6 receptor inhibitors
Time of Update: 2021-08-07
This data analysis shows that compared with standard treatment, the use of these drugs can reduce the chance of death by 13% in severe or critically ill patients .
Retrieved July 7, 2021, from https:// -07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access[2] Interleukin-6 Inhibitors.
-
Several executives of Bikang Pharmaceutical resign
Time of Update: 2021-08-07
On July 7, Yanan Bikang Pharmaceutical issued an announcement stating that the board of directors had recently received written resignation reports from Chairman Gu Xiaojia, Vice Chairman Li Jingkun, Directors He Yudong, Deng Qing, Wang Dong, and Vice President Yue Hongbo .
-
Yiling Pharmaceutical won the "Advanced Group for Poverty Alleviation in Hebei Province"
Time of Update: 2021-08-07
Corresponding poverty alleviation and assisting the construction of beautiful villages In terms of counterpart poverty alleviation, Yiling Pharmaceutical has successively invested more than 1 million yuan in infrastructure projects in poor villages .
-
To Biao Bayer!
Time of Update: 2021-08-07
0 Chinese Drug Evaluation DatabaseIn terms of consistency evaluation, Moxifloxacin Hydrochloride and Sodium Chloride Injection has been reviewed by 9 companies, of which 5 companies including Yangzijiang Pharmaceutical Group, Sichuan Kelun Pharmaceutical and Jiangsu Zhengda Fenghai Pharmaceutical have been approved for supplementary applications.
-
Due to controversy!
Time of Update: 2021-08-07
CompilationFan DongdongAs a controversial new drug for Alzheimer’s disease, one month after the approval of Biogen/Biogen’s Aduhelm, the US health regulatory agency updated the new prescription instructions for the drug’s restricted use on Thursday.
-
The original research drug soared by 374%!
Time of Update: 2021-08-07
0 Chinese Drug Evaluation DatabaseChengdu Better Pharmaceuticals has obtained approvals for 3 products in the field of diabetes medication, including Gliclazide tablets (Ⅱ), lipoic acid injection and metformin hydrochloride sustained-release tablets .
-
Yangtze River "overweights" 1 billion anti-epileptic drugs!
Time of Update: 2021-08-07
A few days ago, the official website of CDE showed that the Levetiracetam tablets of Nanjing Hailing Pharmaceutical of Yangtze River Pharmaceutical Group were accepted for the application of imitation 4 types of listing .
-
Qilu, Yuan Dong...Snatching 400 million anti-inflammatory and anti-rheumatic drugs, this Shandong pharmaceutical company enters the market
Time of Update: 2021-08-07
According to data from Meinenet, in 2020, the total sales of coxixib tablets in the terminals of public medical institutions in China and physical pharmacies in Chinese cities will exceed 400 million yuan, and Merck’s market share will exceed 90% .
-
Pfizer wins the copayment lawsuit!
Time of Update: 2021-08-07
CompilationFan DongdongLast summer, Pfizer was accused of helping patients participating in the medical insurance program pay for the expensive cardiac drugs Vyndaqel and Vyndamax by means of subsidies from patient charities, resulting in the payment of nearly $24 million in the federal settlement.
-
Four important points!
Time of Update: 2021-08-07
Medical Network, July 9th.
(Reporters Peng Yunjia and Mu Tiecheng; poster design: Yang Yiqun) Medical Network, July 9th.
(Reporters Peng Yunjia and Mu Tiecheng; poster design: Yang Yiqun)Medicine Medicine Medicine
-
Amgen/BeiGene's new anti-cancer drug approved in China
Time of Update: 2021-08-07
In the subgroup of patients who received only one treatment with other therapies, KRd therapy was more effective, and compared with Rd therapy, it could prolong the average OS by 11.
-
Hunan: 148 drugs including aluminum phosphate will stop reimbursement
Time of Update: 2021-08-07
148 drugs are transferred out of medical insuranceJuly 9, Hunan Medical Insurance Bureau released the "Notice on 2021 Hunan basic medical insurance, industrial injury insurance and maternity insurance digestive medicines adjustment period" .
-
Sichuan: Re-revision of Chinese medicine standards with 9 errata!
Time of Update: 2021-08-07
Medical Network, July 9 News On July 6, the Sichuan Provincial Food and Drug Administration issued a notice regarding corrections to nine Chinese medicine standards including madder .
-
Countdown to Cleanup of Local Medical Insurance Directory!
Time of Update: 2021-08-07
The former star drug of Jichuan Pharmaceutical is difficult to be removed by the local medical insurance catalogueThe former star drug of Jichuan Pharmaceutical is difficult to be removed by the local medical insurance catalogueOn July 6, Jichuan Pharmaceutical issued an announcement stating that the main varieties of Pudilan Anti-inflammatory Oral Liquid and Iron Protein Succinate Oral Solution, a wholly-owned subsidiary of Jichuan Pharmaceutical Group Co.
-
Hengrui Medicine passed the consistency evaluation of generic drugs for 6 drugs within 1 month
Time of Update: 2021-08-07
Medical Network News on May 8 Recently, Hengrui Pharmaceuticals received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, which approved the company's irinotecan hydrochloride injection and palonosetron hydrochloride injection to pass the imitation Consistency evaluation of pharmaceutical quality and efficacy .
-
The Food and Drug Administration is no longer entangled with millions of penalties, more in the future
Time of Update: 2021-08-07
After a year of entanglement, the Food and Drug Administration began to release itself, no longer entangled, millions of penalties came along with it, and large fines were flying like rain .
-
Universal targeted drugs can reduce the risk of disease progression and death by 78%
Time of Update: 2021-08-07
Clinical trial results show that cabozantinib can significantly prolong the progression-free survival of radioiodine-refractory DTC patients who have previously received VEGFR-targeted therapy, and can significantly reduce the risk of disease progression or death .
-
Renhe Pharmaceutical won multiple companies for 719 million
Time of Update: 2021-08-07
It can be seen that in the first quarter of 2021, the national economy is generally stable, and the economic environment for the development of China's large-scale health industry is showing a good trend, and it has become a good choice for pharmaceutical companies to cross-border to the large-scale health field .
-
Urgent notice!
Time of Update: 2021-08-06
Announcements have been issued in many places, and the new crown vaccination records will be checked in July! Those who have not been vaccinated are not allowed to enter and leave these places, are in
-
Tonghua Dongbao Insulin Aspart 50 applied for listing
Time of Update: 2021-08-06
On July 13, the CDE official website showed that Tonghua Dongbao’s insulin aspart 50 was declared for listing .
This is the first domestically reported insulin aspart 50 in addition to the original research .
